Rhenman & Partners Asset Management AB Has $2.78 Million Holdings in Annexon, Inc. (NASDAQ:ANNX)

Rhenman & Partners Asset Management AB lowered its holdings in shares of Annexon, Inc. (NASDAQ:ANNX) by 3.1% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 542,500 shares of the company’s stock after selling 17,500 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Annexon were worth $2,783,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. E Fund Management Co. Ltd. boosted its stake in Annexon by 36.0% in the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock valued at $79,000 after purchasing an additional 4,086 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of Annexon during the 4th quarter valued at approximately $98,000. Arizona State Retirement System bought a new position in shares of Annexon in the 4th quarter valued at $102,000. Teacher Retirement System of Texas bought a new position in Annexon in the fourth quarter valued at about $106,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Annexon during the 4th quarter worth approximately $116,000.

Annexon Price Performance

ANNX opened at $1.69 on Friday. Annexon, Inc. has a 1 year low of $1.66 and a 1 year high of $7.85. The firm’s fifty day moving average price is $2.81 and its two-hundred day moving average price is $4.82. The company has a market capitalization of $185.41 million, a price-to-earnings ratio of -1.61 and a beta of 1.24.

Annexon (NASDAQ:ANNX) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). As a group, equities analysts anticipate that Annexon, Inc. will post -0.96 EPS for the current year.

Wall Street Analysts Forecast Growth

ANNX has been the topic of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Annexon in a report on Tuesday, December 17th. Needham & Company LLC reiterated a “buy” rating and set a $16.00 price objective on shares of Annexon in a report on Tuesday, March 4th.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.